Drug of Abuse (DOA)

Multi-Drug Screening Cup (2-14 panel)

Detects Multi-analyte. colloidal-gold. Specimen: Urine.

Target / Analyte	Multi-analyte
Disease / Indication	Workplace drug screening
Series	Drug of Abuse (DOA)
Method	colloidal-gold
Specimen	Urine
Test time	10–15 min (product-specific)
Storage	2–30 °C, sealed pouch with desiccant
Shelf life	24 months (product-specific)
Regulatory	CE (IVDD 98/79/EC)
OEM/ODM	Available — private label & custom panel

Direct Answer

This rapid test detects Multi-analyte in Urine to support Workplace drug screening. It is a colloidal-gold screening test — a reactive result is presumptive and should be confirmed per the intended use.

Intended Use

Integrated multi-drug screening cup (2–14 analytes) with adulteration checks.

Clinical Context

Workplace and clinical multi-panel screening with built-in adulteration strips (pH, specific gravity, oxidants).

Test Principle

Colloidal-gold immunochromatography (lateral flow). The device captures the target analyte (antigen or antibody) on a membrane via labeled antibodies, producing a visible test line within minutes. Qualitative or semi-quantitative, intended as a screening/triage aid — not a replacement for confirmatory laboratory testing.

Limitations

Panel is presumptive; any positive analyte requires confirmatory testing.

Procurement

Specimen: urine. Format: cup, 2–14 panel. CE-marked line.

Interpretation

Result	Lines	Meaning
Positive	Test + control line	Target detected (presumptive positive)
Negative	Control line only	Below cut-off / not detected
Invalid	No control line	Repeat with a new device

Common misconception

A reactive drug-screen result is presumptive — it does not indicate impairment, timing of use or a diagnosis. Confirm positives by GC-MS/LC-MS.

Sources

Screening results are presumptive, not diagnostic. Confirmatory testing follows WHO, CDC and national regulatory guidance — see screening vs confirmatory.

Available SKUs (this series)

Cat. No.	Product	Specimen	Format	Kit Size	Status
DOA-125	Multi-Drug 2 Drugs Rapid Test Cassette	Urine	Cassette	25 T	CE
DOA-135	Multi-Drug 3 Drugs Rapid Test Cassette	Urine	Cassette	25 T	CE
DOA-145	Multi-Drug 4 Drugs Rapid Test Cassette	Urine	Cassette	25 T	CE
DOA-155	Multi-Drug 5 Drugs Rapid Test Cassette	Urine	Cassette	25 T	CE
DOA-165	Multi-Drug 6 Drugs Rapid Test Cassette	Urine	Cassette	25 T	CE
DOA-175	Multi-Drug 7 Drugs Rapid Test Cassette	Urine	Cassette	25 T	CE
DOA-185	Multi-Drug 8 Drugs Rapid Test Cassette	Urine	Cassette	25 T	CE
DOA-195	Multi-Drug 9 Drugs Rapid Test Cassette	Urine	Cassette	25 T	CE
DOA-1105	Multi-Drug 10 Drugs Rapid Test Cassette	Urine	Cassette	25 T	CE
DOA-1115	Multi-Drug 11 Drugs Rapid Test Cassette	Urine	Cassette	25 T	CE
DOA-1125	Multi-Drug 12 Drugs Rapid Test Cassette	Urine	Cassette	25 T	CE
DOA-124	Multi-Drug 2 Drugs Rapid Test Panel	Urine	Panel	25 T	CE

Technical Evidence

Analytical performance	Sensitivity, specificity, cut-off and precision are documented per product line in the datasheet and validation report.
Average accuracy	≥96% (overall agreement rate, manufacturer-validated). Per-product sensitivity and specificity are documented in the datasheet.
Clinical performance	Evaluation data (study population, reference method, agreement) available on request.
Cross-reactivity	Documented per analyte — see limitations above.
Documents	IFU · Datasheet · Certificate · Declaration of Conformity — request below.

Buyer Information

MOQ	Product-dependent — low MOQ available on specialty assays
OEM / private label	Custom branding, cut-off, panel and packaging
Samples	Available for evaluation — request via RFQ
Lead time	On request
Documents	IFU · Datasheet · COA · Validation report · CE files · Registration support

Related knowledge

Documentation & quotation — datasheet, IFU, certificate, MOQ and OEM/ODM options on request.

Request IFU / Spec Sheet Request Datasheet Request Certificate

Last reviewed: 2026-09-12